Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
Luisina Castelli Rodríguez, Guillermo Morera, Sandra Lupo, Danilo Davyt, Ignacio Carrera, Gonzalo Hernández Dossi
ACS Omega November 10, 2025 DOI: 10.1021/acsomega.5c07092 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Method development and validation study Peer reviewed |
|---|---|
| Population | Dried Psilocybe cubensis mushrooms (user-provided and laboratory-grown samples) |
| Topics | Psilocybin |
| Keywords | Tryptamines Extraction chemistry Folium of descartes Solid phase extraction Chromatography Quantitative analysis chemistry Hallucinogen |
| Citations | 1 |
| Key points | qNMR spectroscopy provides a rapid, calibration-free method for quantifying psilocybin and psilocin in dried Psilocybe cubensis, revealing significant variability in alkaloid content and ratios between samples. |
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical investigation for the treatment of depression and other psychiatric conditions. However, the accurate quantification of these alkaloids in fungal matrices remains analytically challenging. Here, we report an optimized extraction protocol and a robust, nondestructive quantification method based on quantitative nuclear magnetic resonance (qNMR) spectroscopy. Using a combination of 1H- and 31P NMR, we achieved simultaneous detection and quantification of psilocin and psilocybin in dried Psilocybe cubensis samples with high accuracy and reproducibility. Our method revealed significant variability in tryptamine content and psilocybin-to-psilocin ratios among user-provided and laboratory-grown samples, underscoring the potential influence of storage conditions on alkaloid stability. Compared with conventional chromatographic approaches, qNMR offers a rapid and calibration-free alternative for the routine analysis of psychedelic fungi. This approach may facilitate quality control in emerging clinical and regulatory contexts of psychedelic mushrooms.
Citations in the library
Cites 22
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- DARK Classics in Chemical Neuroscience: Psilocybin ACS Chemical Neuroscience June 29, 2018
- Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research November 1, 2023
- Therapeutic effect of psilocybin in addiction: A systematic review Frontiers in Psychiatry February 9, 2023
and 17 more in the library